The investigational drug MTS-004, crafted by MediTec Therapeutics utilizing its proprietary AI-driven small molecule formulation optimization platform, AiTEM, has triumphantly reached the primary endpoint in its Phase III clinical study. This milestone marks MTS-004 as China's inaugural AI-assisted formulation drug to successfully navigate through Phase III clinical trials. Furthermore, it stands as the first and sole PBA (assuming PBA is a specific medical term or acronym used in the context, if not, it should be defined or replaced with the full term) drug in China to accomplish this feat, poised to bridge the gap left by the absence of approved medications in the domestic PBA treatment landscape. As a groundbreaking oral PBA therapeutic candidate, MTS-004 boasts a proprietary orally disintegrating tablet formulation. This innovative design effectively overcomes patients' swallowing challenges, thereby enhancing the overall medication experience and fostering greater treatment compliance.